{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:06:41Z","timestamp":1791472001685,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81690261"],"award-info":[{"award-number":["81690261"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jconrel.2018.03.019","type":"journal-article","created":{"date-parts":[[2018,3,25]],"date-time":"2018-03-25T23:20:44Z","timestamp":1522020044000},"page":"173-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"special_numbering":"C","title":["A brain targeting functionalized liposomes of the dopamine derivative N -3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson's disease"],"prefix":"10.1016","volume":"277","author":[{"given":"Mengke","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9118-5394","authenticated-orcid":false,"given":"Zhirong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.03.019_bb0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnerability in Parkinson disease","volume":"18","author":"Surmeier","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0010","doi-asserted-by":"crossref","DOI":"10.1126\/science.1255555","article-title":"Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Abeta, tau, and alpha-synuclein","volume":"349","author":"Goedert","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2018.03.019_bb0015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1087753","article-title":"Molecular pathways of neurodegeneration in Parkinson's disease","volume":"302","author":"Dawson","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2018.03.019_bb0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ana.24011","article-title":"Therapeutic prospects for Parkinson disease","volume":"74","author":"Olanow","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0025","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0140-6736(16)31470-2","article-title":"Global, regional, and national levels of maternal mortality, 1990\u20132015: a systematic analysis for the global burden of disease study 2015","volume":"388","author":"Nicholas J Kassebaum","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2018.03.019_bb0030","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrneurol.2015.123","article-title":"Cell-based therapies for Parkinson disease-past insights and future potential","volume":"11","author":"Barker","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0035","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0040","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1179\/1743132811Y.0000000032","article-title":"Protective effects of baicalein against excess L-DOPA-induced dopamine quinone neurotoxicity","volume":"33","author":"Takeshima","year":"2011","journal-title":"Neurol. Res."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0045","doi-asserted-by":"crossref","first-page":"E2517","DOI":"10.1073\/pnas.1502740112","article-title":"Targeting beta-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease","volume":"112","author":"Urs","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0050","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.neurobiolaging.2011.06.019","article-title":"Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias","volume":"33","author":"Fabrizio Gardonia","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jconrel.2018.03.019_bb0055","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1755-5949.2008.00058.x","article-title":"Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson's disease","volume":"14","author":"Hadjiconstantinou","year":"2008","journal-title":"CNS Neurosci. & Ther."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0060","first-page":"1226","article-title":"Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease","volume":"36","author":"Hiroto Kuwabara","year":"1995","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2018.03.019_bb0065","first-page":"216","article-title":"Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease","volume":"37","author":"Tatsuya Ishikawa","year":"1996","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0070","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1021\/mp500352p","article-title":"Brain-specific delivery of dopamine mediated by n,n-dimethyl amino group for the treatment of Parkinson's disease","volume":"11","author":"Li","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0075","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","article-title":"Modern methods for delivery of drugs across the blood-brain barrier","volume":"64","author":"Chen","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0080","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/med.21252","article-title":"Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery","volume":"33","author":"Vlieghe","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0085","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/10611861003734001","article-title":"Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB)","volume":"19","author":"Ulbrich","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0090","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nnano.2012.237","article-title":"Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface","volume":"8","author":"Salvati","year":"2013","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0095","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1016\/j.biomaterials.2010.03.011","article-title":"A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery","volume":"31","author":"Liu","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.03.019_bb0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nature05901","article-title":"Transvascular delivery of small interfering RNA to the central nervous system","volume":"448","author":"Kumar","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2018.03.019_bb0105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pneurobio.2004.09.006","article-title":"Neuronal nicotinic receptors: from structure to pathology","volume":"74","author":"Gotti","year":"2004","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0110","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0115","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.biomaterials.2011.12.017","article-title":"Target delivery of a gene into the brain using the RVG29-oligoarginine peptide","volume":"33","author":"Gong","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.03.019_bb0120","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1016\/j.biomaterials.2009.02.051","article-title":"Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles","volume":"30","author":"Liu","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.03.019_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/srep17543","article-title":"Targeted exosome-mediated delivery of opioid receptor mu siRNA for the treatment of morphine relapse","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0130","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.actbio.2013.11.003","article-title":"Study and evaluation of mechanisms of dual targeting drug delivery system with tumor microenvironment assays compared with normal assays","volume":"10","author":"Gao","year":"2014","journal-title":"Acta Biomater."},{"issue":"60","key":"10.1016\/j.jconrel.2018.03.019_bb0135","first-page":"e3234","article-title":"Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson's disease","author":"Thiele","year":"2012","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0140","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jconrel.2016.06.005","article-title":"MicroRNA-124 loaded nanoparticles enhance brain repair in Parkinson's disease","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2018.03.019_bb0145","first-page":"17","article-title":"Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells","volume":"1130","author":"Rachel","year":"2007","journal-title":"Brain Res."},{"issue":"6","key":"10.1016\/j.jconrel.2018.03.019_bb0150","first-page":"474","article-title":"Immortalized mouse brain endothelial cell line Bend.3 displays the comparative barrier characteristics as the primary brain microvascular endothelial cells","volume":"12","author":"He","year":"2010","journal-title":"Chin. J. Contemp. Pediatr."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-017-0149-0","article-title":"The SH-SY5Y cell line in Parkinson's disease research: a systematic review","volume":"12","author":"Xicoy","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0160","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pep.2014.09.001","article-title":"Production and characterization of a fusion peptide derived from the rabies virus glycoprotein (RVG29)","volume":"104","author":"Yang","year":"2014","journal-title":"Protein Expr. Purif."},{"issue":"1","key":"10.1016\/j.jconrel.2018.03.019_bb0165","first-page":"015","article-title":"Preliminary study on glioma-targeting ability of RVG29-modified liposome","volume":"30","author":"Qi-fang","year":"2015","journal-title":"W. China J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0170","author":"Ailing"},{"key":"10.1016\/j.jconrel.2018.03.019_bb0175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijpharm.2011.07.021","article-title":"Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery","volume":"419","author":"Qin","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0180","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.neuint.2008.12.002","article-title":"A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes","volume":"54","author":"Nakagawa","year":"2009","journal-title":"Neurochem. Int."},{"issue":"4","key":"10.1016\/j.jconrel.2018.03.019_bb0185","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1021\/mp800049w","article-title":"Pharmacokinetics and biodistribution of nanoparticles","volume":"5","author":"Huang","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0190","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1471-4159.2006.04241.x","article-title":"Dopamine and adult neurogenesis","volume":"100","author":"Borta","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jconrel.2018.03.019_bb0195","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/1742-2094-9-193","article-title":"Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis","volume":"9","author":"Jeffrey H Mills","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jconrel.2018.03.019_bb0200","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0167-4889(84)90115-0","article-title":"Creatine Kinase in Regulation of Heart Function and Metabolism","volume":"803","author":"Saks","year":"1984","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2018.03.019_bb0205","first-page":"99","article-title":"Practical guidelines for examination of adults with asymptomatic hypertransaminasaemia","volume":"40","author":"Miguel","year":"2017","journal-title":"Gastroenterol. Hepatol. (Engl. Ed.)"},{"key":"10.1016\/j.jconrel.2018.03.019_bb0210","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.fct.2011.04.011","article-title":"Rhein protects against acetaminophen-induced hepatic and renal toxicity","volume":"49","author":"Yan-Ling Zhao","year":"2011","journal-title":"Food Chem. Toxicol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918301482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918301482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T19:49:52Z","timestamp":1660679392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918301482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":42,"alternative-id":["S0168365918301482"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.03.019","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A brain targeting functionalized liposomes of the dopamine derivative N-3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}